Our first clinical focus is recurrent platinum-resistant ovarian cancer. Ovarian cancer is relatively uncommon, representing an estimated 1.3 percent of new cancer cases diagnosed each year. Unfortunately, most patients with ovarian cancer are diagnosed with advanced-stage disease, when metastasis has already occurred.
Although clinical complete remissions are often achieved through a combination of surgery and chemotherapy, relapse and drug resistance are common. Thus, there is considerable need for new therapies for the treatment of ovarian cancer in this relapsed, second-line setting.
Aravive Clinical Trials
Aravive is currently conducting clinical investigations of its lead compound, AVB-500, in combination with standard anticancer treatments, in the setting of recurrent, platinum-resistant ovarian cancer. For more information on our clinical trials, please visit the study page at www.clinicaltrials.gov.